Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arbutus Biopharma Corp shares valued at $32,637 were sold by MANCHESTER KEITH S on Aug 14 ’24. At $3.69 per share, MANCHESTER KEITH S sold 8,846 shares. The insider’s holdings dropped to 46,069 shares worth approximately $0.15 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Sims Karen sold 4,358 shares, netting a total of over 10,078 in proceeds. Following the sale of shares at $2.31 each, the insider now holds 125,542 shares.
Before that, HASTINGS DAVID C had sold 9,593 shares from its account. In a trade valued at $22,184, the Chief Financial Officer traded Arbutus Biopharma Corp shares for $2.31 each. Upon closing the transaction, the insider’s holdings decreased to 9,593 shares, worth approximately $0.58 million.
As published in a research note from Jefferies on February 02, 2022, Arbutus Biopharma Corp [ABUS] has been rated up from a Hold to a Buy and the price target has been revised to $5. Analysts at Jefferies started covering the stock with ‘”a Hold”‘ outlook in a report released in late February. As of December 17, 2020, H.C. Wainwright has initiated its “Buy” rating for ABUS.
Analyzing ABUS Stock Performance
During the last five days, there has been a drop of approximately -12.36%. Over the course of the year, Arbutus Biopharma Corp shares have jumped approximately 27.60%. Shares of the company reached a 52-week high of $4.72 on 09/09/24 and a 52-week low of $2.21 on 01/17/24. A 50-day SMA is recorded $3.74, while a 200-day SMA reached $3.44. Nevertheless, trading volume fell to 0.99 million shares from 1.19 million shares the previous day.
Support And Resistance Levels for Arbutus Biopharma Corp (ABUS)
According to the 24-hour chart, there is a support level at 3.06, which, if violated, would cause prices to drop to 2.93. In the upper region, resistance lies at 3.39. The next price resistance is at 3.59. RSI (Relative Strength Index) is 32.62 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.15, which suggests the price will decrease in the coming days. Percent R is at 90.91%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
